Press Releases – NASDAQ (US) Website

Apr 28, 2021

BRUKINSA® (Zanubrutinib) Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia read more...

Apr 21, 2021

BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous NonSmall Cell Lung Cancer in China read more...

Apr 12, 2021

BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021 read more...

Apr 11, 2021

BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021 read more...

Apr 08, 2021

BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress read more...

Apr 08, 2021

BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia read more...

Apr 07, 2021

BeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics Facility in Guangzhou, China read more...

Mar 30, 2021

BeiGene Announces New Chief Financial Officer, Julia Wang read more...

Mar 10, 2021

BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021 read more...

Mar 10, 2021

BeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025 read more...

Mar 05, 2021

BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer read more...

Mar 02, 2021

Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia read more...

Feb 26, 2021

BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan read more...

Feb 25, 2021

BeiGene Reports Fourth Quarter and Full Year 2020 Financial Results read more...

Feb 17, 2021

Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists read more...

Feb 17, 2021

BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenström’s Macroglobulinemia read more...

Jan 27, 2021

BeiGene Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma read more...

Jan 26, 2021

EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT® (Siltuximab for Injection) in China read more...

Jan 13, 2021

China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer read more...

Jan 11, 2021

BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab read more...